格隆汇8月18日丨天津发展(00882.HK)宣布，公司将于2025年8月28日(星期四)举行董事会会议，藉以(其 中包括)批准发布公司及其附属公司截至2025年6月30日止六个月的中期业绩公告，以及考虑派发中期股 息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） 董事會召開日期 天津發展控股有限公司（「 本公司 」）董事會（「 董事會 」）謹此 宣佈，本公司將於二零二五年八月二 十八日（星期四）舉行董事會 會議，藉以（其中包括）批准 發佈本公司及其附屬公司截至 二零二五年六月三十日止六個月之中 期業績公告，以及考慮派發中 期股息（如有）。 承董事會命 天津發展控股有限公司 主席及執行董事 滕 飛 香港，二零二五年八月十八日 於本公告日期，本公司董事會包括滕飛先生、翟欣翔博士、夏濱輝先生、 孫利軍先生 * 、伍綺琴女士 ** 、黃紹開先生 ** 、樓家強先生 ** 及 冼漢廸先生 ** 。 * 非執行董事 ** 獨立非執行董事 （股份代號： 882） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 天津發展控股有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / 減少 ...

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), has entered into several wealth management agreements with Industrial Bank, totaling a principal amount of RMB 185 million (approximately HKD 201 million) for investment products [1] Group 1 - On March 31, 2025, Lifescience Pharmaceutical entered into its first wealth management agreement with Industrial Bank, with a principal amount of RMB 20 million (approximately HKD 21.74 million) for structured deposits [2] - On May 7, 2025, Lifescience Pharmaceutical signed its second wealth management agreement with Industrial Bank and Xinyin Wealth Management, with a principal amount of RMB 10 million (approximately HKD 10.87 million) for fixed income investment products [2] - On May 7, 2025, Lifescience Pharmaceutical entered into its third wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 7, 2025, Lifescience Pharmaceutical signed its fourth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On May 29, 2025, Lifescience Pharmaceutical entered into its fifth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 35 million (approximately HKD 38.04 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its sixth wealth management agreement with Industrial Bank for structured deposits, with a principal amount of RMB 50 million (approximately HKD 54.35 million) [2] - On June 11, 2025, Lifescience Pharmaceutical entered into its seventh wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 10 million (approximately HKD 10.87 million) [2] - On June 11, 2025, Lifescience Pharmaceutical signed its eighth wealth management agreement with Industrial Bank and Xinyin Wealth Management for fixed income investment products, with a principal amount of RMB 40 million (approximately HKD 43.48 million) [2]

Group 1 - A batch of non-road mining dump trucks produced by Inner Mongolia North Heavy Industries Group Co., Ltd. has completed export leasing procedures at Tianjin Dongjiang Customs and is being shipped overseas from Tianjin Port [1] - Tianjin Dongjiang Customs has established a rapid customs clearance mechanism, completing the customs procedures in just one day by providing guidance on various business processes [1] - The leasing trade, as an important part of emerging trade formats, allows domestic companies to expand international markets and reduce financial pressure on lessees, with Tianjin's leasing trade import and export volume reaching 14.58 billion yuan, a year-on-year increase of 247.9% [1] Group 2 - Financial institutions in Tianjin, such as Agricultural Bank of China Tianjin Branch, are actively supporting the development of leasing trade, with a leasing business balance exceeding 18 billion yuan and new investments of over 5.5 billion yuan this year [2] - The bonded leasing model in Tianjin has been promoted to other regions like Shanghai, Guangzhou, and Chongqing, forming an annual bonded leasing industry worth hundreds of billions [2] - In 2024, Tianjin Customs' bonded leasing model was selected as one of the first pilot projects for the "Smart Customs Strong Country" initiative by the General Administration of Customs [2]

Financial Performance - The consolidated profit attributable to shareholders for the year ended December 31, 2024, is approximately HKD 548.1 million, down from HKD 635.6 million in the previous year, representing a decrease of 13.8%[22] - Total revenue for 2024 is HKD 3,359 million, a slight increase of 0.6% compared to HKD 3,338 million in 2023[20] - The utility segment reported revenue of HKD 1,444 million, a decrease of 9.8% from HKD 1,600 million in 2023[20] - The pharmaceutical segment achieved revenue of HKD 1,609 million, an increase of 11.7% from HKD 1,441 million in 2023[20] - The company’s mechanical and electrical segment reported a loss of HKD 104 million, compared to a loss of HKD 29 million in the previous year, indicating a significant decline in performance[21] - The revenue from the thermal energy segment decreased by 11.6% to approximately HKD 1,139,400,000, with profit dropping to about HKD 24,700,000[37] - The electricity segment's revenue was approximately HKD 2,399,400,000, a decrease of 4.2%, contributing a profit of about HKD 57,500,000[38] - The profit from the pharmaceutical segment was approximately HKD 443,300,000, compared to HKD 370,100,000 last year, with a comparable profit of approximately HKD 105,000,000 for 2023 after excluding one-time impacts[40] Dividends and Shareholder Returns - The board has proposed a final dividend of HKD 0.0882 per share, bringing the total dividend for the year to HKD 0.14 per share, an increase of 14.3% from the previous year[22] - The board proposed a final dividend of HKD 0.0882 per share for the year ending December 31, 2024, compared to HKD 0.0880 per share in 2023, resulting in a total annual dividend of HKD 0.14 per share, up from HKD 0.1225 in 2023[61] Strategic Focus and Development - The company plans to focus on steady development of existing businesses and pursue high-quality growth through mergers and acquisitions and restructuring[23] - The company will also concentrate on businesses with development potential and sustainable expansion[23] - The company remains optimistic about future growth despite external uncertainties, emphasizing a commitment to prudent financial management and business integration[29] - The company is committed to leveraging its leadership's diverse expertise to drive growth and innovation in its operations[70] Acquisitions and Investments - The acquisition of a 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. was completed, enhancing the production platform for traditional Chinese medicine[24] - The group completed the acquisition of 65% of Qingchun Kangyuan on February 1, 2024, with a performance commitment ensuring audited net profit of no less than RMB 11,332,200 for the fiscal year 2023[41] Employee and Management Changes - Dr. Zhai Xinxiang appointed as Executive Director and General Manager on September 29, 2023, bringing extensive experience in economic and corporate management[65] - Mr. Xia Binhui appointed as Executive Director and Deputy General Manager on December 30, 2024, with a strong background in asset management and corporate restructuring[66] - Mr. Sun Lijun, a senior accountant, serves as the financial director, bringing rich experience in financial management and capital management[67] - The group employed approximately 2,729 employees as of December 31, 2024, an increase from 2,376 in 2023, including 259 management and 894 technical personnel[58] Environmental, Social, and Governance (ESG) Practices - The company has a strong focus on environmental, social, and governance (ESG) practices, adhering to the Hong Kong Stock Exchange's guidelines for ESG reporting[76] - The ESG report covers the period from January 1, 2024, to December 31, 2024, focusing on key operational categories such as public utilities, pharmaceuticals, and electromechanical sectors[77] - The company emphasizes the importance of sustainability in its daily operations and has established a governance framework for implementing various ESG policies and initiatives[80] - The company aims to provide balanced and fair information regarding its ESG performance, avoiding misleading presentations[81] Risk Management - The company has established a clear risk management framework to identify, assess, and manage significant risks, including ESG and climate-related risks[86] - The board is committed to maintaining an effective risk management system, with annual reviews to assess its effectiveness[86] - The company has engaged external consultants for regular independent reviews of its risk management and internal control systems[84] Community Engagement and Social Responsibility - Community investment initiatives include volunteer activities and donations to support vulnerable groups, enhancing social responsibility efforts[165] - The company organized various social activities, including providing safe and reliable water supply services to disabled elderly individuals, demonstrating its commitment to community welfare[165] Corporate Governance - The board consists of eight members, including three executive directors and four independent non-executive directors, ensuring a diverse professional background[172] - The company has maintained compliance with the corporate governance code throughout the year, reflecting its commitment to high governance standards[167] - The board has conducted an annual review of the independence of all independent non-executive directors, confirming their compliance with independence criteria[173] Training and Development - The company provided training for 2,158 employees, totaling 68,894 hours in fiscal year 2024, a decrease from 83,225 hours for 1,926 employees in fiscal year 2023[153] - The overall training participation rate for fiscal year 2024 was 86.35%, down from 89.04% in fiscal year 2023, with an average training hours per employee of 27.57, compared to 38.48 hours in the previous year[153] Compliance and Ethical Standards - The company has established a zero-tolerance policy towards money laundering and has implemented written policies to manage key operational processes[95] - No significant non-compliance issues related to corruption and money laundering were found during the reporting period, reflecting the company's commitment to ethical business practices[163]

Financial Performance - Revenue for the year ended December 31, 2024, was approximately HKD 3,359,416,000, a slight increase from HKD 3,338,429,000 in 2023[3] - Profit attributable to owners of the company was approximately HKD 548,069,000, down from HKD 635,634,000 in the previous year, representing a decrease of about 13.8%[3] - Basic earnings per share decreased to HKD 0.5109 from HKD 0.5925, reflecting a decline of approximately 13.5%[3] - The net profit for the year was HKD 801,165,000, down from HKD 982,537,000 in 2023, indicating a decrease of about 18.4%[5] - Other comprehensive income for the year was a loss of HKD 626,900,000, compared to a gain of HKD 234,211,000 in the previous year[5] - The annual profit for 2024 reached HKD 548,069,000, a decrease of 13.75% compared to HKD 635,634,000 in 2023[23] Dividends - The proposed final dividend is HKD 0.0882 per share, leading to a total annual dividend of HKD 0.14 per share, an increase of approximately 14.3% compared to HKD 0.1225 in 2023[3] - The interim dividend for 2024 was set at HKD 5.18 per share, compared to HKD 3.45 per share in 2023, representing a 50.15% increase[24] - The total dividends declared for the year amounted to HKD 149,973,000, up from HKD 96,013,000 in 2023, indicating a growth of 56.25%[24] - The company proposed a final dividend of HKD 8.82 per share for the year ending December 31, 2024, compared to HKD 8.80 per share in 2023, a slight increase of 0.23%[24] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 22,192,849,000, a slight decrease from HKD 22,292,679,000 in 2023[7] - Current liabilities increased to HKD 4,494,073,000 from HKD 2,827,869,000, indicating a significant rise in short-term obligations[7] - The company's total equity decreased to HKD 17,455,293,000 from HKD 17,512,928,000, reflecting a decline of approximately 0.3%[7] - Total liabilities as of December 31, 2024, were HKD 4,737,556,000, down from HKD 4,779,751,000 in 2023[16] Segment Performance - The operating profit (loss) before interest for the utilities segment is HKD 30,579,000, while the pharmaceuticals segment shows a significant operating profit of HKD 491,053,000[13] - Revenue from external customers in the utilities segment was HKD 1,599,849,000, while the medical segment generated HKD 1,441,437,000[14] - Revenue from the water supply segment decreased by 2.2% to approximately HKD 304,300,000, while profit increased by 8.1% to HKD 17,300,000 due to reduced administrative expenses[36] - Revenue from the thermal energy segment decreased by 11.6% to approximately HKD 1,139,400,000, with profit dropping to HKD 24,700,000 from HKD 35,900,000, primarily due to a reduction in government subsidies[37] - The electricity segment reported revenue of approximately HKD 2,399,400,000, a decrease of 4.2%, with profit contribution falling to HKD 57,500,000 from HKD 63,000,000[38] - Pharmaceutical segment revenue increased by 11.7% to approximately HKD 1,609,700,000, driven by a 14.8% increase in sales of chemical and traditional Chinese medicines[39] Investments and Financial Management - The company recognized a gain of approximately HKD 350,233,000 due to the dilution of its interest in a joint venture, reflecting a significant financial impact[25] - The fair value of listed equity securities decreased to HKD 84,228,000 in 2024 from HKD 99,952,000 in 2023, a decline of 15.73%[26] - The non-listed equity securities increased to HKD 2,181,392,000 in 2024 from HKD 1,619,566,000 in 2023, reflecting a growth of 34.67%[26] - The group employed approximately 2,729 employees as of December 31, 2024, an increase from 2,376 employees in 2023[55] Compliance and Governance - The financial statements for the two years received an unqualified opinion from the independent auditor, indicating no significant issues[9] - The company has not early adopted any new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective[11] - The group has complied with the corporate governance code as per the listing rules throughout the year[61] - The audit committee consists of four independent non-executive directors who regularly review the group's accounting principles and risk management[64] Future Outlook - The company expects stable economic development in China despite external uncertainties, emphasizing a commitment to prudent financial management and business integration[51] - The company plans to continue expanding its market presence in China, where revenue was HKD 3,225,190,000, slightly up from HKD 3,208,051,000 in 2023[17]

Financial Performance - Revenue for the first half of 2024 was HKD 1,820,260, a slight decrease of 0.4% compared to HKD 1,830,477 in the same period of 2023[23] - Gross profit for the period was HKD 588,491, down 2.4% from HKD 601,023 year-on-year[23] - Net profit for the period was HKD 384,330, representing a decrease of 20.4% from HKD 482,313 in the previous year[24] - Basic earnings per share decreased to HKD 26.85, down from HKD 34.63 in the same period last year, reflecting a decline of 22.5%[23] - The company reported a net loss from other comprehensive income of HKD 134,905, compared to a gain of HKD 253,123 in the previous year[24] - The financial expenses increased to HKD 57,837, up from HKD 44,543, marking a rise of 29.8%[23] - The share of profit from associates and joint ventures was HKD 257,003, down 26.2% from HKD 348,173 in the previous year[23] Cash Flow and Assets - Net cash used in operating activities for the six months ended June 30, 2024, was HKD (346,107), compared to HKD (960,310) for the same period in 2023, indicating an improvement[30] - The company reported a net cash outflow from investing activities of HKD (296,030) for the first half of 2024, slightly better than HKD (332,296) in the previous year[30] - Cash and cash equivalents decreased to HKD 3,847,064 as of June 30, 2024, down from HKD 4,461,089 at the beginning of the year[30] - Total assets as of June 30, 2024, amounted to HKD 22,134,547, a decrease from HKD 22,292,679 as of December 31, 2023[25] - The company's total equity decreased to HKD 17,274,287 from HKD 17,512,928, reflecting a decline of approximately 1.36%[26] - The company’s total liabilities increased to HKD 4,860,260 from HKD 4,779,751, representing a rise of approximately 1.69%[26] Segment Performance - Total revenue for the six months ended June 30, 2024, reached HKD 1,820,260,000, with contributions from utilities (HKD 768,660,000), pharmaceuticals (HKD 895,352,000), hotels (HKD 66,555,000), and electromechanical (HKD 89,693,000) segments[49] - The operating profit (loss) before interest for the same period was HKD 94,891,000, with the utilities segment contributing HKD 50,422,000 and pharmaceuticals HKD 88,046,000[49] - Net profit attributable to the company's owners for the six months was HKD 298,087,000, with significant contributions from the electromechanical segment (HKD 155,067,000) and utilities (HKD 82,369,000)[49] - The pharmaceutical segment reported revenue of approximately HKD 895.4 million for the six months ended June 30, 2024, an increase of 7.4% compared to HKD 833.4 million in the same period last year[103] - The hotel segment's revenue increased by 10.3% to approximately HKD 66.6 million, with a profit of approximately HKD 15.2 million, up from HKD 12.2 million in the same period last year[105] Strategic Focus and Future Outlook - The company plans to focus on expanding its utility services and exploring new investment opportunities in the healthcare sector[18] - The company is actively pursuing strategic investments and partnerships to enhance its market position and operational efficiency[18] - Future outlook remains cautious due to market volatility and economic uncertainties, with a focus on cost management and operational improvements[18] - The company plans to continue expanding its market presence and investing in new technologies to enhance operational efficiency and service offerings[49] Compliance and Governance - The financial statements are prepared based on Hong Kong Financial Reporting Standards and comply with the relevant disclosure requirements of the Hong Kong Stock Exchange[31] - The group has adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2024, which include significant changes in lease liabilities and classification of liabilities[33] - The independent auditor reviewed the unaudited condensed consolidated financial statements for the six months ended June 30, 2024, ensuring compliance with Hong Kong Accounting Standards[130] - The audit committee discussed the effectiveness of the company's risk management and internal control systems, including environmental, social, and governance risks[124] Investments and Acquisitions - The company completed the acquisition of a 65% stake in Qingshunkangyuan Group for RMB 136,991,855 (approximately HKD 150,706,000) on February 29, 2024, gaining control over the company.[79] - The preliminary fair value of the acquired assets from Qingshunkangyuan Group includes properties valued at HKD 59,772,000, land use rights at HKD 11,479,000, and intangible assets at HKD 61,481,000.[81] - From the acquisition date to June 30, 2024, Qingshunkangyuan Group contributed revenue of HKD 132,567,000 and net profit of HKD 6,742,000 to the company.[81] Shareholder Information - The major shareholder, Tianjin TEDA Investment Holding Co., Ltd., holds a 62.81% stake in the company as of June 30, 2024[119] - The company declared an interim dividend of HKD 5.18 per share, totaling approximately HKD 55,569,500, compared to HKD 3.45 per share and HKD 37,011,000 in the same period of 2023[62] - The company has committed to maintaining direct or indirect control by the Tianjin State-owned Assets Supervision and Administration Commission, holding more than 50% of the company's majority shares, as part of its financing agreements[126]

Financial Performance - Revenue for the six months ended June 30, 2024, was approximately HKD 1,820,260,000, a decrease of 0.4% from HKD 1,830,477,000 for the same period in 2023[1] - Profit attributable to the company's owners was approximately HKD 288,077,000, down 22.5% from HKD 371,509,000 in the previous year[1] - Basic earnings per share decreased to HKD 26.85 from HKD 34.63, representing a decline of 22.5%[1] - Operating profit (before interest) for the six months ended June 30, 2024, was HKD 94,891, compared to HKD 108,449 in the previous year, reflecting a decrease of about 12.4%[19] - The company reported a net profit of HKD 384,330,000 for the period, down from HKD 482,313,000, a decrease of 20.4%[4] - The basic and diluted earnings per share attributable to the company's owners for the six months ended June 30, 2024, were HKD 288,077, compared to HKD 371,509 for the same period in 2023, representing a decrease of approximately 22.4%[26] Dividends - Interim dividend per share increased to HKD 5.18, compared to HKD 3.45 for the same period last year, reflecting a 50.4% increase[1] - The interim dividend declared for the six months ended June 30, 2024, is HKD 5.18 per ordinary share, an increase from HKD 3.45 per share for the same period in 2023, totaling approximately HKD 55,569,500[27] - The interim dividend declared for the six months ended June 30, 2024, was HKD 0.0518 per share, an increase from HKD 0.0345 per share for the same period in 2023[59] Income and Expenses - Gross profit for the period was HKD 588,491,000, down from HKD 601,023,000, indicating a decrease of 2.1%[3] - Other income increased to HKD 149,223,000 from HKD 143,851,000, showing a growth of 3.0%[3] - Total employee benefits expenses, including directors' remuneration, rose to HKD 298,463 for the six months ended June 30, 2024, compared to HKD 255,799 in the previous year, reflecting an increase of about 16.6%[25] - Research and development expenses included in other operating expenses were HKD 74,400 for the six months ended June 30, 2024, down from HKD 87,375 in the same period of 2023, indicating a decrease of approximately 14.9%[25] - Tax expenses for the six months ended June 30, 2024, totaled HKD 32,465, a slight decrease from HKD 34,408 in the same period of 2023[24] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 22,134,547,000, a slight decrease from HKD 22,292,679,000 at the end of 2023[5] - Cash and cash equivalents decreased to HKD 3,847,064,000 from HKD 4,461,089,000, a decline of 13.8%[5] - Inventory increased to HKD 389,302,000 from HKD 318,690,000, reflecting a growth of 22.1%[5] - Total equity as of June 30, 2024, is HKD 17,274,287, a decrease of 1.36% from HKD 17,512,928 as of December 31, 2023[6] - Total liabilities increased to HKD 4,860,260, up 1.69% from HKD 4,779,751 as of December 31, 2023[6] - Current assets net amount is HKD 7,578,530, down 3.21% from HKD 7,830,868 as of December 31, 2023[6] - Non-current liabilities include bank loans of HKD 1,713,074, slightly up from HKD 1,710,630[6] - Accounts payable increased to HKD 558,532, a rise of 7.74% from HKD 518,398[6] - Other payables and accrued expenses rose to HKD 1,367,464, an increase of 5.61% from HKD 1,294,865[6] - Contract liabilities decreased to HKD 513,717, down 18.73% from HKD 632,444[6] - The company reported a total asset minus current liabilities of HKD 19,163,581, a decrease from HKD 19,464,810[6] Segment Performance - The company operates in six reportable segments, including utilities, pharmaceuticals, hotels, electromechanical, port services, and elevators[11] - The company’s water supply segment reported revenue of approximately HKD 142,300,000, a decrease from HKD 153,000,000 in the previous year, with a profit increase of 6.4% to HKD 18,400,000[42] - The thermal power segment's revenue decreased by 10.9% to approximately HKD 626,400,000, while profit increased to HKD 40,400,000 due to improved operating profit margins[43] - The electricity segment reported a revenue decrease of 3% to approximately HKD 1,143,500,000, contributing a profit of HKD 28,300,000, a decrease of HKD 1,100,000 from the previous year[44] - The pharmaceutical segment reported revenue of approximately HKD 895.4 million for the six months ending June 30, 2024, an increase of 7.4% compared to HKD 833.4 million in the same period last year[45] - Revenue from the production and sale of chemical drugs, traditional Chinese medicine, and other health products was approximately HKD 811.4 million, up 9.9% from HKD 738 million year-on-year, primarily driven by increased contributions from Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd.[45] - The profit for the pharmaceutical segment was approximately HKD 62.3 million, down from HKD 79.4 million in the previous year[45] - The revenue from the drug research institute decreased by 52% to approximately HKD 130.2 million, resulting in a loss of approximately HKD 50.9 million, compared to a loss of HKD 33.5 million in the same period last year[45] - The hotel segment, Hong Kong Courtyard Hotel, reported revenue of approximately HKD 66.6 million, a 10.3% increase from HKD 60.4 million year-on-year, with a profit of approximately HKD 15.2 million compared to HKD 12.2 million last year[48] - The electromechanical segment reported revenue of approximately HKD 89.7 million, an increase of 11.6% from HKD 80.4 million, but incurred a loss of approximately HKD 58 million, worsening from a loss of HKD 21.8 million in the previous year[49] - Tianjin Port Development Holdings Limited's revenue increased by 8.1% to approximately HKD 6.7463 billion, while the attributable profit decreased by 12% to approximately HKD 418.5 million[50] - Otis Elevator (China) reported revenue of approximately HKD 8.7909 billion, a decrease of 1.4% year-on-year, with a profit contribution of approximately HKD 155.1 million, down 23.4% from the previous year[51] Investments and Acquisitions - On June 28, 2024, the company agreed to sell 24.65% equity in Tianjin Tanabe Pharmaceutical Co., Ltd. for RMB 120,292,000 (approximately HKD 131,755,000) to Yuanda Pharmaceutical (China) Co., Ltd.[38] - The company sold 15% equity in Tianjin Pharmaceutical Group Finance Co., Ltd. for RMB 87,824,000 (approximately HKD 96,192,000) to Jin Yao Da Ren Tang Group Co., Ltd. as of December 31, 2023, with the sale still pending completion as of June 30, 2024[38] - The company conditionally agreed to acquire 65% equity in Qingchun Kangyuan Group for a total cash consideration of RMB 136,991,855 (approximately HKD 150,706,000), completed in February 2024[39] - From the acquisition of Qingchun Kangyuan Group, the company recorded revenue of HKD 132,567,000 and net profit of HKD 6,742,000 from the acquisition date to June 30, 2024[40] Financial Position and Strategy - The company expects to continue focusing on market expansion and new product development to drive future growth[20] - The company anticipates continued stable development in the Chinese economy due to the implementation of various reform measures, while maintaining a prudent and proactive strategy for long-term growth[54] - As of June 30, 2024, the total cash and bank loans of the group were approximately HKD 6,174,100,000 and HKD 1,972,700,000, respectively, compared to HKD 6,604,700,000 and HKD 1,810,600,000 as of December 31, 2023[55] - The debt-to-equity ratio as of June 30, 2024, was approximately 15.8%, up from 14.4% as of December 31, 2023[55] - The group had outstanding bank loans totaling HKD 1,972,700,000, with HKD 1,713,100,000 linked to sustainability performance indicators[55] - The group has pledged restricted bank deposits of HKD 144,400,000 and properties, plants, and equipment valued at HKD 6,500,000 as collateral for general bank credit facilities[57] - The group is actively monitoring foreign exchange rate fluctuations to manage its foreign exchange risk[55] - The group did not enter into any derivative contracts or hedging transactions during the review period[55] - The group has complied with the corporate governance code as per the listing rules throughout the review period[62]

Financial Performance - The pharmaceutical business generated approximately HKD 1,441,400,000 in revenue, with a profit of about HKD 370,100,000 for the year[25]. - The company recorded a one-time gain of approximately RMB 238,597,000 (equivalent to about HKD 265,108,000) from the sale of industrial land and properties in Tianjin[11]. - The public utility segment reported revenue of HKD 1,600,000,000, a decrease of 13.9% compared to HKD 1,859,000,000 in the previous year[28]. - The hotel segment saw a significant increase in revenue, rising 66.7% to HKD 130,000,000 from HKD 78,000,000[28]. - The company’s total revenue for the year was HKD 3,338,000,000, down 9.9% from HKD 3,705,000,000 in the previous year[28]. - The audited consolidated profit attributable to shareholders for the year ended December 31, 2023, is approximately HKD 635.6 million, an increase from HKD 358.2 million in the previous year, representing an 77.5% growth[56]. Dividends and Shareholder Returns - The board has proposed a final dividend of HKD 0.088 per share, with total dividends for the year amounting to HKD 0.1225 per share, a 37% increase compared to 2022[56]. - The board of directors will consider the group's financial performance, earnings, distributable reserves, future prospects, and other relevant factors when establishing an appropriate dividend distribution policy[131]. - The group has adopted a dividend policy, which allows the board to decide on the declaration and payment of dividends, subject to compliance with applicable regulations[152]. - The board proposed a final dividend of HKD 0.088 per share for the year ended December 31, 2023, compared to HKD 0.055 per share in 2022, resulting in a total annual dividend of HKD 0.1225 per share, up from HKD 0.0895 per share in 2022[192]. Business Segments and Operations - The electromechanical business faced challenges, with revenue declining by 40.6% to approximately HKD 167,000,000, continuing to record operating losses[32]. - The port services segment reported revenue of HKD 153,000,000, an increase of 83% compared to HKD 70,000,000 in the previous year[23]. - The pharmaceutical segment was recognized as a "National Enterprise Technology Center," highlighting its innovation and research capabilities[25]. - The company acquired a 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., enhancing its production capabilities in traditional Chinese medicine[30]. - The public utility business performance was stable and met expectations, benefiting from the high-quality innovative development and industrial structure upgrade in the Tianjin Economic-Technological Development Area[45]. Corporate Governance and Compliance - The company has maintained a high level of corporate governance to protect shareholder interests and has complied with the corporate governance code throughout the year[74]. - The company strictly adheres to the Good Manufacturing Practice (GMP) and other relevant laws and regulations in the pharmaceutical sector[67]. - The company emphasizes the importance of a complete and timely reporting system and internal controls, with the board playing a key role in implementing and monitoring financial controls[82]. - The board is responsible for maintaining an effective risk management and internal control system, which is reviewed annually to ensure compliance with applicable laws and regulations[99]. - The company has a policy to ensure that the roles of the chairman and CEO are distinct and not held by the same individual[81]. Risk Management and ESG Initiatives - The company has established an Environmental, Social, and Governance (ESG) working group to oversee the implementation of ESG policies and strategies[101]. - The board is committed to reviewing and managing ESG-related risks continuously to ensure effective internal control systems[101]. - The company aims to reduce air emissions and water discharge intensity by 5% per RMB 1,000 revenue by 2025 compared to the fiscal year 2019[102]. - The company targets a 5% reduction in hazardous waste generation intensity per RMB 1,000 revenue by 2025 compared to the fiscal year 2019[102]. - The company plans to decrease electricity consumption intensity in electromechanical, pharmaceutical, and utility categories by 5% per RMB 1,000 revenue by 2025 compared to the fiscal year 2019[102]. Management and Leadership - Teng Fei was appointed as the chairman of the board on March 27, 2024, and has extensive experience in enterprise management, particularly in manufacturing[197]. - Dr. Zhai Xinxiang was appointed as the executive director and general manager on September 29, 2023, bringing rich experience in economics and public relations[198]. - The management team is committed to leveraging their extensive experience to drive the company's growth and operational efficiency[197][198]. Employee and Operational Metrics - The company employed approximately 2,376 employees as of December 31, 2023, a decrease from 2,490 employees in 2022[189]. - The company has implemented various health and safety measures across its major subsidiaries[59]. - The company has initiated an online continuing education program to enhance the knowledge of professional technicians in the pharmaceutical sector[60]. Financing and Capital Structure - A financing agreement was signed on February 1, 2023, for a revolving loan of HKD 100,000,000, which does not have a fixed term[137]. - The company signed a financing letter for a term loan of HKD 300,000,000 on December 5, 2022, with a maturity of twelve months from the first drawdown[158]. - A financing agreement was signed with a syndicate for a term loan with a ceiling of HKD 2,500,000,000 (including an overloan facility) on December 7, 2022, with a maturity of thirty-six months from the drawdown[160]. - The company pledged restricted bank deposits of HKD 216.9 million as collateral for general bank credit facilities, up from HKD 178.9 million in 2022[190].